These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 25608146)

  • 1. Rhabdoid papillary meningioma treated with 177Lu DOTATATE PRRT.
    Makis W; McCann K; McEwan AJ
    Clin Nucl Med; 2015 Mar; 40(3):237-40. PubMed ID: 25608146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extraventricular neurocytoma treated with 177Lu DOTATATE PRRT induction and maintenance therapies.
    Makis W; McCann K; McEwan AJ
    Clin Nucl Med; 2015 Mar; 40(3):234-6. PubMed ID: 25608145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esthesioneuroblastoma (olfactory neuroblastoma) treated with 111In-octreotide and 177Lu-DOTATATE PRRT.
    Makis W; McCann K; McEwan AJ
    Clin Nucl Med; 2015 Apr; 40(4):317-21. PubMed ID: 25674857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymoma treated with 177Lu DOTATATE induction and maintenance PRRT.
    Makis W; McCann K; McEwan AJ
    Clin Nucl Med; 2015 May; 40(5):e278-81. PubMed ID: 25783505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lung Metastases of Intracranial Atypical Meningioma Diagnosed on Posttherapeutic Imaging After 177Lu-DOTATATE Therapy.
    Backhaus P; Huss S; Kösek V; Weckesser M; Rahbar K
    Clin Nucl Med; 2018 Jun; 43(6):e184-e185. PubMed ID: 29688946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response assessment of somatostatin receptor targeted radioligand therapies for progressive intracranial meningioma.
    Müther M; Roll W; Brokinkel B; Zinnhardt B; Sporns PB; Seifert R; Schäfers M; Weckesser M; Stegger L; Stummer W; Rahbar K
    Nuklearmedizin; 2020 Sep; 59(5):348-355. PubMed ID: 32691404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRRT with Lu-177 DOTATATE in Treatment-Refractory Progressive Meningioma: Initial Experience from a Tertiary-Care Neuro-Oncology Center.
    Puranik AD; Dev ID; Rangarajan V; Kulkarni S; Shetty N; Gala K; Sahu A; Bhattacharya K; Dasgupta A; Chatterjee A; Gupta T; Sridhar E; Sahay A; Shetty P; Singh V; Moiyadi A; Menon N; Purandare NC; Agrawal A; Shah S; Choudhury S; Ghosh S; Jha AK
    Neurol India; 2024 Mar; 72(2):278-284. PubMed ID: 38691470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete Resolution of Neuroendocrine Tumor Soft Tissue Metastases After 177Lu DOTATATE PRRT Induction and Maintenance Therapy.
    Makis W; McCann K; Buteau FA; McEwan AJ
    Clin Nucl Med; 2015 Aug; 40(8):663-6. PubMed ID: 25546219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medullary thyroid carcinoma (MTC) treated with 177Lu-DOTATATE PRRT: a report of two cases.
    Makis W; McCann K; McEwan AJ
    Clin Nucl Med; 2015 May; 40(5):408-12. PubMed ID: 25674858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
    Parghane RV; Talole S; Prabhash K; Basu S
    Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ectopic Corticotropin-Producing Neuroendocrine Tumor of the Pancreas Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy.
    Makis W; McCann K; Riauka TA; McEwan AJ
    Clin Nucl Med; 2016 Jan; 41(1):50-2. PubMed ID: 26359569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.
    Seystahl K; Stoecklein V; Schüller U; Rushing E; Nicolas G; Schäfer N; Ilhan H; Pangalu A; Weller M; Tonn JC; Sommerauer M; Albert NL
    Neuro Oncol; 2016 Nov; 18(11):1538-1547. PubMed ID: 27106404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastatic Insulinoma Pancreatic Neuroendocrine Tumor Treated With 177Lu-DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy: A Suggested Protocol.
    Makis W; McCann K; McEwan AJ
    Clin Nucl Med; 2016 Jan; 41(1):53-4. PubMed ID: 26562579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Will
    Braat AJAT; Snijders TJ; Seute T; Vonken EPA
    Cardiovasc Intervent Radiol; 2019 Nov; 42(11):1649-1652. PubMed ID: 31187231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up.
    Severi S; Grassi I; Bongiovanni A; Nicolini S; Marini I; Arpa D; Ranallo N; Azzali I; Di Iorio V; Sarnelli A; Manuela M; Amadori E; Fabbri L; Bartolini D; Tosatto L; Di Meco F; Gurrieri L; Riva N; Calabro L; Matteucci F; Paganelli G; Sansovini M
    J Nucl Med; 2024 Sep; 65(9):1409-1415. PubMed ID: 39142827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
    Ranade R; Basu S
    J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver and bone metastases from small bowel neuroendocrine tumor respond to 177Lu-DOTATATE induction and maintenance therapies.
    Makis W; McCann K; Buteau FA; McEwan AJ
    Clin Nucl Med; 2015 Feb; 40(2):162-5. PubMed ID: 25243941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors.
    Hamiditabar M; Ali M; Bolek L; Vahdati G; Tworowska I; Delpassand ES
    Clin Nucl Med; 2017 Nov; 42(11):822-828. PubMed ID: 28832377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagonoma Pancreatic Neuroendocrine Tumor Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy.
    Makis W; McCann K; Riauka TA; McEwan AJ
    Clin Nucl Med; 2015 Nov; 40(11):877-9. PubMed ID: 26204206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged response to
    Cottereau AS; Bricaire L; Arrondeau J; Dechmi A; Montravers F; Coriat R; Clerc J; Groussin L; Tenenbaum F
    Invest New Drugs; 2020 Aug; 38(4):1196-1199. PubMed ID: 31650444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.